Amulet IDE Trial Supports Abbott’s New LAA Closure Device
Results of the trial showed Amplatzer Amulet was superior to Boston Scientific’s Watchman for left-atrial appendage closure and noninferior for safety and effectiveness.
You may also be interested in...
June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.
Amplatzer Amulet is a percutaneous transcatheter device designed to prevent thrombus embolization from the left-atrial appendage in people with nonvalvular atrial fibrillation.
The PINNACLE FLX trial of the next-generation WATCHMAN left atrial appendage closure device met its primary safety and effectiveness endpoints with a low adverse event rate of 0.5%.